Testing inhibitors of the IFN-γ-chemokine axis as new treatments for vitiligo.
Prof. J. Harris, MD. University of Massachusetts Medical School, USA. Jan 2013 - Dec 2015. The project aims to test some new substances for vitiligo treatment using a unique mouse model of vitiligo. If successful, this could be a critical step towards developing a new approach to vitiligo treatment. Publication: PMID: 24523323
Isolation, characterization and differentiation of human dermal stem cells into functional epidermal melanocytes in vitiligo patients.
Prof. D. Parsad, MD. Department of Dermatology, Post Graduate Institute for Medical Education and Research, Chandigarh, India. Jan 2013 - Dec 2013. The study aims to evaluate safety of multipotent dermal stem cells in dermis of lesional vitiligo skin. Further exploration of new approaches to stimulate dermal stem cells (reservoirs of new melanocytes) can help to discover novel approaches in vitiligo treatment.
Extraction of Melanin from hair for making camouflage and pigment for tattoo.
Prof. C.R. Srinivas, Dept. of Dermatology, PSG Institute of Medical Science & Research, Peelamedu, Tamilnadu, India. Jan 2013 - Dec 2013. The study aims to develop a new method for vitiligo treatment: the extraction of melanin from patients own hair, which will then be used as a camouflage cream or pigment for tattoo for vitiliginous skin.
Triple combination treatment with fractional CO2 laser plus topical betamethasone injection and NB-UVB for stable vitiligo on extremities and/or bony prominences – a prospective, randomized half-body, comparative study.
Prof. Y. Wu, MD. Department of Dermatology, No.1 Hospital of China Medical University, Shenyang, China. Sep 2013 - Aug 2014. Based on the previous pilot study results the project aims to acknowledge the safety and efficiency of triple combination fractional CO2 laser + betamethasone + NB-UVB for stable vitiligo on heavy depigmented lesions. The project will experimentally validate new method of vitiligo treatment.
CCR6 in the pathogenesis of vitiligo – a possible novel therapeutic target in vitiligo.
Prof. Y. Hong, No. 1 Hospital of China Medical University, Shenyang, China. Sep 2013 - Aug 2014. Based on findings that Th17 cells are involved in the development autoimmune diseases, including vitiligo, and genetic association of CCR6 gene variations with vitiligo, the project aims to evaluate whether Th17 cells functioning CCR6/CCL20 axis is involved in vitiligo pathogenesis with respect to vitiligo sability. The project can promote the development of new diagnostic tool for vitiligo stability.
Benvitimod cream for the treatment of vitiligo: a clinical and experimental pilot study.
Prof. J. Du, Peking University People’s Hospital, Beijing, China. Sep 2013 - Aug 2014. The study aims to evaluate the efficiency of newly synthesized small molecule Benvitimod for vitiligo treatment. The study may facilitate the discovery of a new method for vitiligo treatment.